Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
AI Proteins Secures $41.5M Series A to Accelerate AI‑Driven Drug Discovery
Series AVenture Capital

AI Proteins Secures $41.5M Series A to Accelerate AI‑Driven Drug Discovery

•November 20, 2025
•Nov 20, 2025
0

Participants

AI Proteins

AI Proteins

company

Mission BioCapital

Mission BioCapital

investor

Santé

Santé

investor

Cobro

Cobro

investor

Lightchain Capital

Lightchain Capital

investor

Why It Matters

The sizable raise underscores growing investor confidence in AI‑enabled drug discovery, positioning AI Proteins to potentially shorten development timelines and capture market share in the competitive protein therapeutics space.

Deal Summary

Boston‑based AI Proteins announced a $41.5 million Series A round led by Mission BioCapital and Santé Ventures, with participation from Lightchain Capital, Cobro Ventures and other existing backers. The funding will be used to expand operations, boost R&D and advance its AI‑enabled protein therapeutics platform.

0

Comments

Want to join the conversation?

Loading comments...